Separately, a Phase 1/2a clinical trial (NCT01718899) reported that the PVX-410 vaccine enhanced anti-tumor immunity in SMM patients by increasing the proportion of tetramer-positive and interferon-γ-producing CD3+CD8+ T cells [130]. The gene discussed is CD8A; the disease is neoplasm.